Birtcher Medical Systems
This article was originally published in The Gray Sheet
Executive SummaryVP of Research and Design Harold J. Walbrink is promoted to the new position of senior VP of operations and technology. In addition, Corporate Controller Anita Ryan is named VP finance and chief accounting officer of Birtcher. Ryan will assume "certain responsibilities" of Daniel Whelan, who has resigned from the posts of VP, chief financial officer and corporate secretary, effective Sept. 30, in order "to pursue personal opportunities." Birtcher Chairman David B. Jones will add the titles of CFO and corporate secretary with Whelan's departure. Birtcher also promotes John Bottjer, international regional director for Latin America, to the new post of director, international sales
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.